Navigation Links
ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
Date:6/27/2011

MOUNTAIN VIEW, Calif., June 27, 2011 /PRNewswire/ -- ChemoCentryx, Inc. today announced that the Company's novel CCR2 antagonist significantly improves kidney function and hyperglycemia in experimental models.  These data implicate CCR2-driven processes in the pathology of type 2 diabetes and associated complications such as diabetic nephropathy.  Results were highlighted in a poster presentation entitled "CCR2 Antagonism Improves Renal Function and Hyperglycemia in Preclinical Models of Type 2 Diabetes" at the 71st Scientific Session of the American Diabetes Association held in San Diego.  CCX140, the Company's lead novel, orally available CCR2 antagonist, successfully met its primary endpoint of safety and tolerability in a Phase II clinical trial in type 2 diabetes, while demonstrating clinical activity on glycemic indices following only 28 days of treatment.  CCX140 is currently poised to enter Phase II clinical development for the treatment of diabetic nephropathy.

"In the United States there are more than 31 million patients living with chronic kidney disease, 37% as a result of having diabetes," stated Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "Complicating matters further is the fact that the current standard of care does not stop or reverse progression and with the increasing number of patients who progress to end-stage renal disease each year -- there is a clear demand for better treatment options.  We believe these data demonstrate compelling rationale to move forward CCX140, our most advanced CCR2 antagonist, in a Phase II clinical trial for the treatment of diabetic nephropathy."

CCR2 inhibition was studied in two models of type 2 diabetes:  diet-induced obese mice and db/db mice. Treatment with the CCR2 antagonist significantly improved multiple metabolic/renal parameters in obese, diabetic mice, including hyperglycemia, insulin sensitivity, serum adiponectin, glucosuria, albuminuria and serum markers (creatinine and BUN) of renal function.  The metabolic improvements correlated with a significant reduction in adipose tissue macrophage numbers.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors.

Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, CCX282 (Traficet-EN, now designated GSK1605786, also known as GSK'786), a specific CCR9 antagonist, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development.  CCX140, a CCR2 antagonist, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetes.  CCX140 is poised to enter Phase II clinical development for the treatment of diabetic nephropathy.  Other clinical programs include CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, that completed Phase I clinical development and is anticipated to enter Phase II clinical trials in 2011; and CCX832, a ChemR23 antagonist in Phase I clinical development. ChemoCentryx also has several programs in advanced preclinical development.  ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.

Certain statements in this press release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from those expressed or implied. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
2. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
4. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
5. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
6. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
7. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
8. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
9. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
10. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
11. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 CENTRO DE IMAGEM ... 157, paragraph 4 of Law 6,404/76 and Instruction 358/02 ... informs its shareholders and the market in general that ... subsidiary Centro de Diagnosticos por Imagem Ltda. (" CDI ... interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " and ...
(Date:3/23/2017)... 2017 Ascendis Pharma A/S (Nasdaq: ASND), a ... address significant unmet medical needs in rare diseases, today ... and webcast on Monday, April 3 during ENDO 2017, ... Orlando, Florida , to discuss new data ... Hormone, TransCon PTH and TransCon CNP). Ascendis ...
(Date:3/23/2017)... 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" ... MD announces that AB Laboratories Inc. ("AB Labs") has ... facility under the Access to Cannabis for Medical Purposes ... . The facility, which was licensed ... currently operating at half capacity, with full production capacity ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 2017 , ... Gastro Health (“GH”) ( http://www.gastrohealth.com ) ... colonoscopy at the HyGIeaCare® Center that is to be located adjacent to the ... The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration (FDA), will ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/23/2017)... , ... March 23, 2017 , ... In 2016 the ... estimates that there could be four million Zika-related cases in the Americas within the ... numbers of US cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased ... Building 2. The clinic is the group’s second in New Braunfels and 22nd in ... second New Braunfels location brings things full circle for the group, “It’s crazy to ...
(Date:3/23/2017)... NY (PRWEB) , ... March 23, 2017 , ... 82% of adults are unaware of ... kids do not brush their teeth the minimum two times a day that dentists recommend. ... students missing 51 million hours of school and adults missing 164 million hours of work ...
Breaking Medicine News(10 mins):